Black Rock Inc. Xeris Biopharma Holdings, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 10,332,078 shares of XERS stock, worth $29.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,332,078

Previous 9,960,506 3.73%

Holding current value

$29.7 Million

Previous $22 Million 5.61%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.7 - $2.45 $631,672 - $910,351	371,572 Added 3.73%	10,332,078 $23.2 Million
Q1 2024 May 10, 2024	SELL	$2.04 - $3.22 $103,805 - $163,849	-50,885 Reduced 0.51%	9,960,506 $22 Million
Q4 2023 Feb 13, 2024	BUY	$1.47 - $2.36 $936,609 - $1.5 Million	637,149 Added 6.8%	10,011,391 $23.5 Million
Q3 2023 Nov 13, 2023	BUY	$1.8 - $2.69 $71,362 - $106,647	39,646 Added 0.42%	9,374,242 $17.4 Million
Q2 2023 Aug 11, 2023	BUY	$1.82 - $2.98 $1.68 Million - $2.75 Million	921,416 Added 10.95%	9,334,596 $24.5 Million
Q1 2023 May 12, 2023	SELL	$1.03 - $1.63 $167,923 - $265,743	-163,033 Reduced 1.9%	8,413,180 $13.7 Million
Q4 2022 Feb 13, 2023	BUY	$1.14 - $1.65 $396,246 - $573,515	347,585 Added 4.22%	8,576,213 $11.4 Million
Q3 2022 Nov 14, 2022	BUY	$1.37 - $1.93 $303,912 - $428,139	221,834 Added 2.77%	8,228,628 $12.8 Million
Q2 2022 Aug 12, 2022	BUY	$1.48 - $2.64 $8.9 Million - $15.9 Million	6,011,915 Added 301.37%	8,006,794 $12.3 Million
Q1 2022 May 12, 2022	BUY	$2.0 - $2.87 $398,732 - $572,180	199,366 Added 11.1%	1,994,879 $5.11 Million
Q4 2021 Feb 10, 2022	BUY	$1.8 - $2.93 $3.23 Million - $5.26 Million	1,795,513 New	1,795,513 $5.26 Million

Others Institutions Holding XERS

# of Institutions

133

Shares Held

57M

Call Options Held

126K

Put Options Held

45K

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $390M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account